Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical, Inc. (DE:UP0)
:UP0
Earnings Data
Report Date
Feb 12, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.03Last Year’s EPS
-1.21Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook due to strong financial positioning, consistent revenue growth, and promising pipeline advancements, despite challenges such as net losses and regulatory hurdles.Company Guidance
Strong Financial Position
Ultragenyx received $400 million of nondilutive capital from OMERS, deferring the start of payments until January 2028, which strengthens their financial position.
Consistent Revenue Growth
Ultragenyx's commercial products have delivered consistent double-digit annual revenue growth, with expected total revenue between $640 million and $670 million, representing 14% to 20% growth over last year.
Positive Pipeline Developments
Ultragenyx has 2 BLA submissions in progress and multiple late-stage clinical programs with transformative commercial potential approaching pivotal data readouts.
Crysvita Expansion
Crysvita revenue is expected to grow, with approximately 875 patients on commercial product in Latin America and new patient growth in the United States, Canada, and other regions.
Improvements in Clinical Trials
Positive anecdotal evidence from clinical trials, such as improvements in bone mineral density and patient outcomes with UX143 for osteogenesis imperfecta.
DE:UP0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:UP0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | €28.60 | €23.60 | -17.48% |
Aug 05, 2025 | €25.80 | €25.00 | -3.10% |
May 06, 2025 | €34.00 | €30.80 | -9.41% |
Feb 13, 2025 | €41.40 | €41.40 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ultragenyx Pharmaceutical, Inc. (DE:UP0) report earnings?
Ultragenyx Pharmaceutical, Inc. (DE:UP0) is schdueled to report earning on Feb 12, 2026, TBA (Confirmed).
What is Ultragenyx Pharmaceutical, Inc. (DE:UP0) earnings time?
Ultragenyx Pharmaceutical, Inc. (DE:UP0) earnings time is at Feb 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Ultragenyx Pharmaceutical, Inc. stock?
The P/E ratio of Ultragenyx Pharmaceutical is N/A.
What is DE:UP0 EPS forecast?
DE:UP0 EPS forecast for the fiscal quarter 2025 (Q4) is -1.03.